206 related articles for article (PubMed ID: 26549039)
21. Preparation and in vitro evaluation of thienorphine-loaded PLGA nanoparticles.
Yang Y; Xie XY; Mei XG
Drug Deliv; 2016; 23(3):787-93. PubMed ID: 24870204
[TBL] [Abstract][Full Text] [Related]
22. Modification of the release characteristics of estradiol encapsulated in PLGA particles via surface coating.
Enayati M; Stride E; Edirisinghe M; Bonfield W
Ther Deliv; 2012 Feb; 3(2):209-26. PubMed ID: 22834198
[TBL] [Abstract][Full Text] [Related]
23. Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery.
Wang Y; Li P; Kong L
AAPS PharmSciTech; 2013 Jun; 14(2):585-92. PubMed ID: 23463262
[TBL] [Abstract][Full Text] [Related]
24. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration.
Zhang X; Sun M; Zheng A; Cao D; Bi Y; Sun J
Eur J Pharm Sci; 2012 Apr; 45(5):632-8. PubMed ID: 22248882
[TBL] [Abstract][Full Text] [Related]
25. Formulation and evaluation of butenafine loaded PLGA-nanoparticulate laden chitosan nano gel.
Alshehri S; Imam SS
Drug Deliv; 2021 Dec; 28(1):2348-2360. PubMed ID: 34747275
[TBL] [Abstract][Full Text] [Related]
26. Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential.
Sharma M; Mehta I
Sci Rep; 2019 Nov; 9(1):16105. PubMed ID: 31695118
[TBL] [Abstract][Full Text] [Related]
27. Formulation and in vitro evaluation of bisphosphonate loaded microspheres for implantation in osteolysis.
Samdancioglu S; Calis S; Sumnu M; Atilla Hincal A
Drug Dev Ind Pharm; 2006 Apr; 32(4):473-81. PubMed ID: 16638686
[TBL] [Abstract][Full Text] [Related]
28. Modeling of chitosan modified PLGA atorvastatin-curcumin conjugate (AT-CU) nanoparticles, overcoming the barriers associated with PLGA: An approach for better management of atherosclerosis.
Dash R; Yadav M; Biswal J; Chandra A; Goel VK; Sharma T; Prusty SK; Mohapatra S
Int J Pharm; 2023 Jun; 640():123009. PubMed ID: 37142139
[TBL] [Abstract][Full Text] [Related]
29. Review: approaches to develop PLGA based in situ gelling system with low initial burst.
Ahmed T
Pak J Pharm Sci; 2015 Mar; 28(2):657-65. PubMed ID: 25730797
[TBL] [Abstract][Full Text] [Related]
30. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide.
Wischke C; Zhang Y; Mittal S; Schwendeman SP
Pharm Res; 2010 Oct; 27(10):2063-74. PubMed ID: 20668921
[TBL] [Abstract][Full Text] [Related]
31. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
Zeng P; Xu Y; Zeng C; Ren H; Peng M
Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate.
Yang X; Trinh HM; Agrahari V; Sheng Y; Pal D; Mitra AK
AAPS PharmSciTech; 2016 Apr; 17(2):294-306. PubMed ID: 26085051
[TBL] [Abstract][Full Text] [Related]
33. In vitro schistosomicidal activity of the lignan (-)-6,6'-dinitrohinokinin (DNHK) loaded into poly(lactic-co-glycolic acid) nanoparticles against Schistosoma mansoni.
Lima TC; Lucarini R; Luz PP; de Faria EH; Marçal L; Magalhães LG; Badoco FR; Esperandim VR; Molina EF; Laurentz RS; Lima RG; Cunha WR; Bastos JK; Silva MLA
Pharm Biol; 2017 Dec; 55(1):2270-2276. PubMed ID: 29172838
[TBL] [Abstract][Full Text] [Related]
34. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.
Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S
Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558
[TBL] [Abstract][Full Text] [Related]
35. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.
Ahmed TA; Ibrahim HM; Samy AM; Kaseem A; Nutan MT; Hussain MD
AAPS PharmSciTech; 2014 Jun; 15(3):772-80. PubMed ID: 24648158
[TBL] [Abstract][Full Text] [Related]
36. Anthracycline Drugs on Modified Surface of Quercetin-Loaded Polymer Nanoparticles: A Dual Drug Delivery Model for Cancer Treatment.
Saha C; Kaushik A; Das A; Pal S; Majumder D
PLoS One; 2016; 11(5):e0155710. PubMed ID: 27196562
[TBL] [Abstract][Full Text] [Related]
37. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability.
Badran MM; Alomrani AH; Harisa GI; Ashour AE; Kumar A; Yassin AE
Biomed Pharmacother; 2018 Oct; 106():1461-1468. PubMed ID: 30119220
[TBL] [Abstract][Full Text] [Related]
38. Poly(D,L-lactic-co-glycolic acid)-based artesunate nanoparticles: formulation, antimalarial and toxicity assessments.
Dauda K; Busari Z; Morenikeji O; Afolayan F; Oyeyemi O; Meena J; Sahu D; Panda A
J Zhejiang Univ Sci B; 2017 Nov.; 18(11):977-985. PubMed ID: 29119735
[TBL] [Abstract][Full Text] [Related]
39. Prediction of dexamethasone release from PLGA microspheres prepared with polymer blends using a design of experiment approach.
Gu B; Burgess DJ
Int J Pharm; 2015 Nov; 495(1):393-403. PubMed ID: 26325309
[TBL] [Abstract][Full Text] [Related]
40. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.
Mehta AK; Yadav KS; Sawant KK
Curr Drug Deliv; 2007 Jul; 4(3):185-93. PubMed ID: 17627492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
